Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

15.53
+0.18001.17%
Post-market: 15.530.00000.00%19:30 EDT
Volume:104.91K
Turnover:1.63M
Market Cap:380.55M
PE:-1.31
High:16.16
Open:15.54
Low:15.20
Close:15.35
52wk High:45.00
52wk Low:10.50
Shares:24.50M
Float Shares:10.79M
Volume Ratio:0.57
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.8281
EPS(LYR):-16.0562
ROE:-93.28%
ROA:-34.18%
PB:1.63
PE(LYR):-0.97

Loading ...

Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)

TIPRANKS
·
Jun 03

Lyell Immunopharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 03

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

GlobeNewswire
·
Jun 01

Lyell Immunopharma (LYEL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Lyell Immunopharma to present at H.C. Wainwright BioConnect investor conference

Reuters
·
May 12

Lyell Immunopharma Announces Participation in May Investor Conferences

GlobeNewswire
·
May 12

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
May 07

Lyell Immunopharma Q1 revenue misses, adjusted net loss narrows

Reuters
·
May 07

Lyell Immunopharma Q1 EPS $(1.10) Beats $(2.19) Estimate, Sales $2.000K Miss $4.400K Estimate

Benzinga Earnings
·
May 07

BRIEF-Lyell Immunopharma Q1 Net Income USD -24.153 Million

Reuters
·
May 07

Lyell Immunopharma Q1 Revenue USD 2 Thousand VS. Ibes Estimate USD 4.4 Thousand

THOMSON REUTERS
·
May 07

Lyell Immunopharma Q1 Operating Income USD -44.261 Million

THOMSON REUTERS
·
May 07

Lyell Immunopharma Q1 Operating Expenses USD 44.263 Million

THOMSON REUTERS
·
May 07

Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Dow Jones
·
May 07

Baird Initiates Lyell Immunopharma at Outperform With $49 Price Target

MT Newswires Live
·
May 01

Lyell Immunopharma announces 2026 annual shareholder meeting webcast

Reuters
·
Apr 25

Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst

TIPRANKS
·
Apr 10

Needham & Co Initiates Coverage on Lyell Immunopharma With Strong Buy Rating, $44 Price Target

MT Newswires Live
·
Apr 10

Lyell Immunopharma Initiated at Buy by Needham

Dow Jones
·
Apr 10

Lyell Immunopharma: Undervalued CAR-T Innovator With Strong Ronde-cel Profile, Hidden LYL273 Upside, and Cash Runway to 2027 Supporting Buy Rating and $44 Target

TIPRANKS
·
Apr 10